B Cell Immunity in Lung Transplant Rejection - Effector Mechanisms and Therapeutic Implications

Birte Ohm1 and Wolfgang Jungraithmayr1,2*

1 Department of Thoracic Surgery, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 2 Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland

Allograft rejection remains the major hurdle in lung transplantation despite modern immunosuppressive treatment. As part of the alloreactive process, B cells are increasingly recognized as modulators of alloimmunity and initiators of a donor-specific humoral response. In chronically rejected lung allografts, B cells contribute to the formation of tertiary lymphoid structures and promote local alloimmune responses. However, B cells are functionally heterogeneous and some B cell subsets may promote alloimmune tolerance. In this review, we describe the current understanding of B-cell-dependent mechanisms in pulmonary allograft rejection and highlight promising future strategies that employ B cell-targeted therapies.

Keywords: lung transplantation, B cell, antibody mediated allograft rejection, chronic lung allograft dysfunction (CLAD), donor-specific antibodies, allosensitization

INTRODUCTION

Lung transplantation is the definite therapeutic option for patients suffering from end-stage lung disease. However, long-term post-transplant survival is limited to approximately 50% after five years due to chronic lung allograft dysfunction (CLAD) (1). Generally, allogeneic immune responses are the barrier to unlimited pulmonary graft acceptance. While T-cell-dependent acute graft rejection is today efficiently prevented by immunosuppression, antibody-mediated rejection (AMR), characterized by the presence of donor-specific antibodies (DSA), remains a poorly controlled risk factor for CLAD development (2). Recently, B cells gained increasing attention as key allogeneic immune effectors via antibody-dependent and -independent mechanisms. B cells produce DSA and autoantibodies against pulmonary self-antigens that have implications in both, AMR and CLAD pathogenesis (2). Apart from inducing humoral immune responses, B cells also act as antigen-presenting cells (APCs) aiding in T cell activation. In chronically rejected allografts, B cells are critical for lymphoid neogenesis and the formation of in-graft tertiary lymphoid organs (TLOs). The latter are believed to promote a local alloimmune response (3).
B cells are functionally heterogeneous and not all subsets contribute to inflammatory graft injury. For example, regulatory B cell populations (Bregs) are thought to be critical mediators of immune homeostasis and graft tolerance (4). B cell-targeted therapeutic approaches could thereby improve long-term outcomes after lung transplantation.

**HUMORAL ALLOIMMUNITY INDUCES COMPLEMENT-DEPENDENT AND –INDEPENDENT GRAFT INJURY**

Preformed antibodies can cause hyperacute rejection with pulmonary allografts developing severe hemorrhagic oedema and radiographic infiltrates in the immediate postoperative period (5). Preformed donor-specific antibodies (DSA) against donor-derived human leukocyte antigen (HLA) molecules can be present in recipients due to prior sensitization (e.g. blood transfusion or pregnancy) or develop de novo upon transplantation.

DSA can be directed against major histocompatibility complex (MHC) class I molecules, such as HLA-A, HLA-B and HLA-C or MHC class II molecules such as HLA-DQ, HLA-DR or HLA-DP (2). Cleary et al. demonstrated recently that the capillary endothelium is the primary target in anti-MHC I-antibody-mediated lung injury in a murine conditional knockout model (6). Notably, pulmonary endothelial cells not only carry MHC I, but also express MHC II antigens under inflammatory conditions (7, 8). The resulting immune complexes on the endothelial surface activate the classical complement pathway by engaging the C1 complex (Figure 1). Consequently, endothelial damage occurs due to the formation of the membrane attack complex (MAC) as the final effector of the complement cascade (9). Exposure of the basal membrane subsequently activates the coagulation cascade causing thrombosis, fibrinoid necrosis, hemorrhagic oedema and loss of graft function. During this process, pulmonary-self antigens are exposed and promote autoimmune responses and further graft damage (10, 11). The activation of the coagulation cascade can also further complement activation due to non-canonical cleavage of the C3 and C5 components (12). In addition, complement activation promotes inflammation by generating the anaphylatoxins C3a and C5a (9). However, not all DSA belong to complement-fixing immunoglobulin subclasses. Different mechanisms of complement-independent humoral allograft injury have been proposed including the release of growth factors that results in endothelial and smooth muscle cell proliferation or platelet activation (13, 14). Furthermore, DSA binding can promote cellular graft damage engaging the Fcγ receptors on natural killer cells, macrophages and neutrophils (15, 16). In lung transplantation, the presence of complement-binding IgG1- and IgG3-DSA is associated with worse post-transplant outcomes (17, 18).

Today, hyperacute rejection is sufficiently prevented by antigen avoidance due to prior detection of pre-formed panel reactive antibodies (PRA) in patients listed for transplantation and pre-transplant crossmatching. However, patients with high PRA titers have a decreased chance of transplantation, prolonged waiting times, and higher waitlist mortality (19). Management strategies for these patients vary significantly among institutions, some of them considering allosensitization even a contraindication to transplantation (20). Other centers employ desensitization techniques such as plasmapheresis or immune adsorption before transplantation with varying success (21). While these strategies may prevent hyperacute graft damage by transient reduction of circulating DSA measured by reduced MFI in DSA detection assays, they have no impact on the spectrum of PRA or the number of antibody-producing cells. As current allocation systems do not consider recipient sensitization, the question arises whether this criterion should be included to reduce waitlist mortality. However, consequentially higher rates of post-transplant complications might be observed. In 2022, the United States is expected to incorporate pre-transplant allosensitization in their allocation system (22).

**FIGURE 1** | Mechanism of humoral allograft rejection. DSA and antibodies bind to their respective antigens and thus activate the complement cascade, promoting inflammation and leading to cellular damage by formation of the membrane attack complex (MAC). Subsequent exposure of pulmonary self-antigens such as Collagen V or K-α1 Tubulin can further initiate autoimmune responses against the graft.
B LYMPHOCYTES INITIATE DE NOVO DSA GENERATION AND MEMORY RESPONSES UPTON TRANSPLANTATION

Upon transplantation, donor-derived antigen-presenting cells (APCs) and extracellular vesicles move to recipient secondary lymphoid organs (SLOs) and initiate an allospecific adaptive immune response. During this process, recipient T cells are activated by donor antigen by means of the direct, indirect or semi-direct allorecognition pathways. Direct allorecognition occurs when recipient T cells recognize intact donor MHC on donor APCs. Due to rapid elimination of donor-derived passenger leukocytes during the early post-transplant period, direct allorecognition is thought to be most relevant for acute rejection. However, the recent discovery of semi-direct allorecognition has challenged this paradigm. Here, recipient APCs acquire functional, intact donor MHC and can thus activate recipient T cells after the demise of passenger leukocytes. However, chronic allograft rejection is primarily a feature of indirect allorecognition in which recipient T cells recognize processed donor-derived antigen presented by recipient APCs (23). T cells activated by indirect allorecognition are subsequently able to translocate to the follicular border of the lymphoid follicle, acquire a T follicular helper cell (Tfh) phenotype and subsequently induce a B cellular response (24–26).

Naïve recipient B lymphocytes circulate to SLOs where they encounter donor antigen binding to their B cell receptor (BCR). Subsequently, the recipient B cell internalizes the donor antigen and processes it for presentation on MHC II. Such antigen-primed B cells express the G-protein coupled Epstein-Barr virus-induced molecule-2 (EBI2) on their surface and are mobilized to the border of the T cell zone (27). Here, they interact with their primed CD4+ T cell counterparts and subsequently undergo different fates: Firstly, short-lived antibody-producing plasma cells are generated. They reside in SLOs and rapidly produce low-affinity anti-donor antibodies. Secondly, B cells can differentiate to germinal center B cells (GC B cells), characterized by the expression of the B cell lymphoma 6 (BCL6) transcription factor. During the germinal center reaction, those B cells undergo clonal expansion, somatic hypermutation and affinity selection and thus generate a highly specific anti-donor response. The germinal center reaction thus results in the generation of memory B cells and long-lived plasma cells (LLPCs), both of which allow for a long-term upkeep of the donor-specific humoral immune response (28).

Memory B cells can be found in the spleen, lymph nodes, and peripheral blood. They reside in a quiescent state and await antigen re-challenge (29). Most memory B cells are class-switched and bind their specific antigen with a higher affinity than their naïve precursors (30). They retain all functional B cell properties and undergo activation, clonal expansion and germinal center reactions in a secondary immune response. Compared to naïve B cells, they show a faster kinetic due to their enhanced reactivation potential. They are thus essential players in allo-sensitization – allowing for rapid enhancement of DSA in pre-sensitized recipients (31). For example, memory B cells are generated during pregnancy and could thus induce a secondary immune response upon solid organ transplantation (32). However, the overall clinical significance of pregnancy-associated sensitization in allograft rejection remains unclear (33).

Apart from memory B cells allowing for the rapid generation of specific antibody upon antigen re-challenge, humoral memory is also mediated by constitutive antibody secretion from LLPCs. LLPCs are terminally differentiated cells and have lost both the ability to proliferate and most B cell-specific surface markers (34). They home to the bone marrow sinusoid niche where they persist for several years or even lifelong (35) and provide long-lasting and specific antibody secretion, even in the absence of their respective antigen (36). To date, there is only little understanding about the mechanisms leading to LLPC longevity. Even though LLPCs acquire an intrinsic transcriptional and metabolic profile that conditions them for long-term survival, continuous external signals from their survival niche are critical to maintain viability (35, 37). Therefore, the generation of LLPCs is conditional on their recruitment to the bone marrow mediated by the CXCL12-CXCR4 axis (38).

By both reactivation of memory B cell responses and generation of LLPCs, lung transplant recipients develop a long-lasting humoral anti-donor immune response causing continuous inflammatory damage to the graft that ultimately leads to acute and chronic rejection (Figure 2).

ANTIBODY-MEDIATED REJECTION CONTRIBUTES TO CHRONIC REJECTION AND POOR OUTCOME AFTER LUNG TRANSPLANTATION

In 2016, the ISHLT consensus consortium defined for the first time the term antibody-mediated rejection (AMR) as a separate entity for pulmonary graft rejection and provided standardized diagnostic criteria (2). A definite diagnosis of AMR requires the diagnosis of clinical allograft dysfunction, the presence of DSA, a characteristic lung pathology, endothelial deposition of complement component C4d, and the exclusion of other causes of graft dysfunction.

Proof of C4d deposition is a controversial diagnostic criterion for pulmonary AMR (39). Most complement components show non-covalent binding to the endothelium and are thus rapidly inactivated by decay-accelerating factor (DAF) and CD59 on the endothelial surface. In contrast, C4d forms a covalent thioester bond making it resistant to shedding and thus detectable by immunohistochemistry. In pulmonary pathology, C4d deposition is not specific to AMR but is also observed during ischemia-reperfusion injury, acute cellular rejection and in the context of infection (40). In addition, not all cases of AMR show positive staining for C4d, giving rise to the descriptive term “C4d-negative” AMR. Whether this is a form of AMR caused by non-complement fixing antibodies or these observations owe to technical limitations of staining practices remains unclear (39).
Summarizing these aspects, AMR is a complex pathologic and clinical process that ultimately leads to acute and chronic loss of graft function. Clinically, AMR-related graft dysfunction can range from fulminant respiratory failure to subclinical dysfunction detected only by surveillance lung function testing (2). As the diagnosis of AMR is associated with increased presence of chronic lung allograft dysfunction (CLAD) (41), it seems likely that continuous humoral graft damage significantly contributes to chronic rejection. In support of this, the application of anti-donor MHC antibodies histologically results in obliterative bronchiolitis (OB) in murine studies (42). In lung transplant recipients with high DSA titers, restrictive allograft syndrome (RAS) is the more common CLAD subtype and often results in rapid and fatal graft failure (43). However, CLAD also occurs in the absence of detectable circulating DSA, and these cases cannot be histologically or clinically distinguished from those with measurable serum DSA. In some of these patients with missing serum DSA, the presence of intragraft DSA can be demonstrated (44, 45). These studies corroborate the importance of the humoral response in RAS as this CLAD phenotype was associated with higher in-graft DSA titers. The reason for the discrepancies between serum and intragraft DSA remains elusive (45). Firstly, they could be attributed to a strong intragraft binding of DSA, and secondly, some authors assign intragraft DSA to a local alloantibody production within the graft.

Infiltrating B cells may promote intragraft alloimmune reactions during chronic rejection

In chronically rejected allografts, infiltrating lymphocytes form cell clusters reminiscent of classical lymphoid follicles (46). This process is termed lymphoid neogenesis and is not only observed in chronically rejected solid organ grafts but also in chronic infection, autoimmune disease, and cancer (47). Generally, these tertiary lymphoid organs (TLOs) are formed when a persistently activated immune system is unable to eradicate its target antigen (48). In chronically rejected lung allografts, TLOs are typically found in patients suffering from restrictive allograft syndrome (RAS) (49). Here, the number of TLOs correlates with a lower life expectancy – indicating a deleterious role for TLOs. Even though the regulation of humoral responses upon transplantation is generally thought to occur peripherally and depend on antigen presentation in secondary lymphoid organs, TLOs are believed to elicit alloimmune responses by similar mechanisms (Figure 2) (50). Compared to secondary lymphoid organs, these processes occur directly within the graft in a microenvironment of abundant alloantigen and self-antigens released upon tissue damage (3). Furthermore, TLOs show restricted lymphatic drainage and are thus believed to trap antigen and initiate a pronounced local immune response (51). As a result, graft-damaging DSA could be generated within the transplant lung.
B cells are critical for maintaining lymphoid structures as B cell-deficient mice show disorganized lymphoid tissues (52). In a murine model of orthotopic single lung transplantation, Smirnova et al. recently demonstrated that the depletion of B cells abrogates TLO formation in pulmonary allografts. In addition, B cell depletion diminished the fibrous tissue remodeling that is characteristic for chronic rejection in this experimental model (53). Inhibition of EBI2 which is known for orchestrating B cell positioning in lymphoid structures, resulted in equal observations (53). Watanabe et al. demonstrated furthermore that B cell depletion diminished humoral immune responses against allo- and autoantigens, TLO formation and fibrosis in a murine orthotopic lung transplantation model of RAS using a minor-mismatched strain combination (54). They demonstrated that B cell depletion only had a minor influence on in-graft T cell composition - pointing towards an even more decisive role for B cells in the development of CLAD lesions (54). However, whether TLOs are a causative agent in CLAD or merely a byproduct of the immune response remains unclear. To date, adequate experimental models that can specifically inhibit lymphoid neogenesis without further targeting recipient immunity are missing. Thus far, it can also be proposed that the formation of TLOs in chronically rejected grafts is a non-specific response to the local inflammatory milieu (3).

**ALLOIMMUNITY-INDUCED AUTOIMMUNITY THROUGH BREAKING B CELL SELF-TOLERANCE**

Non-DSA humoral immune responses have gained interest in graft rejection (55). In principle, all human solid organ allograft recipients have autoantibodies. These antibodies target a wide variety of antigens which may be both ubiquitously present or organ-specifically expressed. In lung transplant recipients, autoantibodies that target fibrillar collagen V (ColV) and K-alpha tubulin (KoT) are associated with increased rates of CLAD (56). These autoantibodies either exist prior to transplantation or can be generated de novo. Their contribution to graft damage remains elusive as they are often accompanied by the presence of DSA (56). It is likely that the alloimmune response facilitates transplant-associated autoimmunity, as the majority of autoimmune target antigens are located in the intracellular compartment and are not expressed as surface molecules. However, antigens translocate to the cell surface upon apoptotic triggers such as previous alloimmune damage. In fact, transplant-associated autoantibody predominantly targets the allograft rather than native organs (57). The development of autoimmune responses requires the breaking of B cell self-tolerance. Even in healthy individuals, clonal deletion and receptor editing in the bone marrow fail to eliminate all autoreactive cells and allow some self-reactive transitional B cells to enter the circulation. Upon antigen encounter, these cells acquire an anergic state that is characterized by limited B cell receptor signal transduction, a reduction of surface IgM and the exclusion from the B cell follicle (58). However, B cell anergy can be broken by CD4+ T cell help (59). Upon transplantation, the encounter of passenger donor CD4+ T cells could trigger autoimmunity by breaking B cell anergy (60). This may prime self-reactive B cells to interact with recipient-derived Tfh cells while subsequently undergoing a germinal center response.

Most likely, intra-graft TLOs contribute significantly to alloimmunity-induced autoimmunity as the abundance of self-antigens within the damaged graft may facilitate the selection of high-affinity mutants during the germinal center response. This way, the plasma cell output is shaped according to locally expressed autoantigen. In autoreactive germinal centers, epitope diversification may spread the autoreactive response to other autoantigens (61). In support of this, Bharat et al. demonstrated that anti-KoT-autoantibody is generated after the application of anti-ColV antibody in a murine model of unilateral lung transplantation (62).

The germinal center response further enhances the number of autoreactive B cells within the allograft. Here, these B cells function as APCs and contribute to graft damage by priming T effector cells (63). Even though antigen presentation by B cells requires the specific engagement of their B cell receptor, they could contribute to the alloimmune response by the uptake of bystander antigen within the graft (64).

**POLYREACTIVE NATURAL ANTIBODIES PUTATIVELY PARTICIPATE IN LUNG ALLOGRAFT REJECTION**

Polyreactive natural antibodies (nAbs) were first identified in the 1960s and play a decisive role in tissue homeostasis and innate immunity. Most nAbs originate from innate-like B1 B cells that primarily reside in the pleural and peritoneal cavities. However, marginal zone B cells and bone marrow precursors also contribute to nAb generation. nAbs include IgM, IgG and IgA isotypes with both germline and somatically mutated sequences (65).

nAbs are known to bind both apoptotic cell structures and pathogenic antigen, and they control damage from oxidative stress. Similar to specific antibodies, nAbs can activate the classical complement pathway and engage Fc receptors (66, 67). With regard to transplantation, nAbs react to ABO blood group antigens and xeno-antigens and are thus responsible for hyperacute rejection in ABO-incompatible- and xeno-transplantation (68). However, their role in allotransplantation is less clear.

Due to their broad binding profile, nAbs are difficult to evaluate and not readily distinguishable from specific antibodies. For example, polyreactive nAbs account in part for serum reactivity to HLA in Luminex assays (69). It is therefore difficult to study the specific role of natural antibodies.

Upon transplantation, nAbs may bind to endothelial neo-antigens exposed upon ischemia-reperfusion injury and recognize the danger-associated molecular patterns (DAMPs) in damaged allografts. In kidney transplantation, the presence of polyreactive nAbs is associated with AMR and graft loss (66, 70).
While most nAbs belong to the IgM isotype in steady-state conditions, IgG nAbs dominate in kidney transplant recipients (71). I seems possible that innate-like B cells can undergo class switching following antigen encounter.

To our knowledge, there is only one study that evaluates the role of polyreactive nAbs in lung transplantation: in contrast to observations made in kidney transplantation, Budding et al. reported that elevated polyreactive nAbs against apoptotic cells in patients with end-stage lung disease do not show any correlation with the presence of acute or chronic allograft rejection (72).

Taken together, natural antibodies may play a role in allograft rejection by recognizing a broad variety of self- and non-self antigens. However, natural antibody responses are difficult to evaluate and their specific contribution to allograft damage remains largely unclear.

**B CELLULAR ANTIGEN PRESENTATION CONTRIBUTES TO ALLOGRAFT REJECTION**

Even though antibody-mediated mechanisms significantly contribute to chronic allograft rejection, Zeng et al. demonstrated that B cells are able to promote chronic rejection independently of antibody production using a murine model of cardiac transplantation (63): while B cell-depleted animals were protected from it, mice lacking circulating antibodies developed chronic allograft vasculopathy. Upon adoptive transfer of B lymphocytes without the ability to produce antibodies, B cell-depleted animals developed chronic rejection (63). These observations may be attributed to the role of B cells as antigen-presenting cells and suggest that they are necessary for optimal priming of alloreactive T cells (73).

B cells are only able to present antigen via the indirect allorecognition pathway. Upon alloantigen engagement, they internalize the specific antigen and process it for presentation on MHC II (74). To our knowledge, MHC cross-dressing and therefore presentation for semi-direct allorecognition has not yet been described in B lymphocytes. Recipient B cells therefore exclusively engage with recipient CD4+ T cells. As described above, such an encounter is crucial for the germinal center response. Apart from this interaction with Tfh cells, it remains unclear whether B cells can function as APCs to other CD4+ effector or regulatory T cells in allogeneic transplantation (74).

**REGULATORY B CELL SUBSETS MEDIATE GRAFT TOLERANCE**

Apart from their detrimental role in allograft rejection, specialized B lymphocyte subsets have been implicated in promoting graft tolerance. These are immunosuppressive B lymphocytes that are collectively termed regulatory B cells (Bregs) and comprise a heterogeneous population of various stages of B cell maturity. Initially defined by the ability to produce interleukin-10 (IL-10), it is now accepted that Bregs also utilize other immunoregulatory cytokines and cell surface receptors (75). To date, characterizing Bregs remains challenging as they lack specific phenotypic or transcriptional markers. Insights into the development of Bregs is therefore limited (76). Whether these cells comprise a separate lineage or if B cells of different states of maturity can acquire regulatory properties under certain conditions is currently unclear (75).

Even though true transplant tolerance in the presence of generalized immunocompetence is not achievable in humans (77), operational tolerance is observed in liver and kidney transplant recipients, demonstrating stable graft function in the absence of maintenance immunosuppression. In these patients, B lymphocyte-related gene signatures have been characterized as biomarkers for operational tolerance (78). Tolerant recipients show reduced DSA titers and decreased numbers of plasma cells, as well as increased numbers of naïve B cells and IL-10+ Bregs in their peripheral blood (79). To date, operational tolerance has not been reported in lung transplantation. However, increased peripheral numbers of IL-10+CD19+ CD24hiCD38hi transitional Bregs in lung transplant recipients were shown to be associated with a decreased risk for chronic rejection (80). These transitional Bregs have been defined to secrete the highest amount of IL-10 upon CD40 stimulation compared to other peripheral B cell subsets (75). In the murine CLAD model of heterotopic tracheal transplantation, an intense infiltration of transitional Bregs upon rapamycin treatment resulted in the prevention of fibrotic airway obliteration (81). These observations suggest that certain B cells mediate tolerogenic signals in lung transplantation and could therefore serve as innovative therapeutic targets in transplant-related diseases.

Mechanistically, Bregs target immune effector cells by both cytokine secretion and ligand-receptor interactions. Even though the nature of Breg interaction with other immune effectors in vivo remains unclear, surface expression of CD40 and MHC II suggests that Bregs interact with T lymphocytes and can therefore modulate T-cell-dependent alloimmunity (82). Engagement of Breg surface Fas ligand (FasL) or PD-L1 by their respective T cellular receptors Fas and PD-1 can induce apoptosis in T effector cells (83, 84). Bregs also indirectly modulate T cell function secreting the anti-inflammatory cytokines IL-10, IL-35 and transforming growth factor β (TGF-β) as well as granzyme B (82). As an anti-inflammatory member of the IL-12 cytokine family, IL-35 has been demonstrated to suppress T cell proliferation and boost the conversion of naïve T cells to IL-35+ regulatory T cells (Tregs) (85). TGF-β can support the generation of Tregs and inhibits effector lymphocyte proliferation (82). Furthermore, granzyme B can modulate effector lymphocyte populations by the induction of apoptosis (86). IL-10 - secreting Bregs (also termed B10 cells) also induce the differentiation and expansion of immunosuppressive regulatory T cells (Tregs) (87) and could thus promote graft tolerance. The tolerogenic properties of regulatory B cells are summarized and contrasted to conventional B cell-mediated rejection in Figure 3.
Taken together, some B lymphocyte subsets can mediate tolerogenic signals regulating T cell functions. Their immunomodulatory function should be considered when applying B cell-targeted therapy in the context of transplantation, as B cell depletion could thus increase the risk of cellular rejection (88).

**STRATEGIES FOR AMR TREATMENT AND DSA REDUCTION**

Even though some may argue that T-cell-focused immunosuppression should curb B cell responses via Tfh cell inhibition, routine post-transplant immunosuppressive regimens fail to control AMR and chronic rejection after lung transplantation. Desensitization and current treatment strategies for pulmonary AMR have been adapted from experiences in other solid organ grafts. The treatment aims to diminish circulating DSA, limit complement activation or tone down B cell activity. Figure 2 provides an overview of the strategies for AMR treatment and DSA reduction.

Plasmapheresis and immunoabsorption are often employed to reduce circulating DSA in highly sensitized recipients (89). While plasmapheresis separates plasma from whole blood, immunoabsorption specifically removes target antibodies from the circulation. However, the rates of DSA reduction are variable, and long-term desensitization cannot be achieved by plasmapheresis alone as antibody production is not suppressed. Indeed, rebound phenomena with heightened antibody production can occur after plasmapheresis (90). Therefore, plasmapheresis should always be used in combination with other therapeutic approaches.

As previously described, antibody-mediated complement activation significantly contributes to humoral graft damage. In addition, complement indirectly drives AMR development as opsonization (e.g. by C3d) is needed for antigen uptake into B cells. Upon BCR engagement, complement receptors act as B-cell coreceptors.

Eculizumab is an inhibitor of the complement component C5 routinely used in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic syndrome (aHUS). In lung transplantation, the use of eculizumab has been employed in combination therapy for AMR (91) and hyperacute rejection (92). Inhibiting C5 cleavage to C5a and C5b, eculizumab can prevent graft damage by impeding MAC formation. However, eculizumab treatment not only limits activation of the classical pathway responsible for graft damage but also affects the alternative complement pathway central to pathogen clearance. Therefore, caution should especially be taken in transplant recipients regarding infectious complications during eculizumab treatment.

C1 esterase inhibitor (C1-INH) targets the classical pathway by blocking the proteolytic activity of C1r and subsequent cleavage of C2 and C4 components. Furthermore, C1-INH has inhibitory effects on the lectin pathway of complement activation, coagulation, kallikrein and kinin systems. In lung transplantation, C1-INH can effectively prevent reperfusion injury and primary graft dysfunction in experimental settings. In human pulmonary AMR, rapid clinical and radiologic improvements upon C1-INH treatment have been reported.
in vitro monoclonal antibody which inhibits complement activation both in vitro (94) and in vivo (95) and reduces C4d deposition in renal AMR (96).

While these strategies reduce antibody-induced complement-mediated damage, they cannot achieve a reduction of antibody titers nor limit complement-independent graft injury. In this regard, IgG endopeptidase cleaves the Fc fragments from human IgG and thus renders them incapable of both complement activation and induction of antibody-dependent cellular cytotoxicity. In kidney transplantation, IgG endopeptidase treatment successfully reduced DSA and allowed successful HLA-incompatible transplantation in highly sensitized recipients (97). As of yet, a use in lung transplantation has not been reported. Even though IgG endopeptidase can reduce DSA titers, it exerts an unspecific effect on all IgG limited to a time period of approximately two weeks. Therefore, its use might not be feasible for preventing chronic humoral alloimmune responses.

Intravenous Immunoglobulin (IVIG) treatment is a commonly used immunosuppressive technique in autoimmune conditions (98) and is routinely employed in desensitization and AMR treatment. However, its precise mechanism of action remains unknown and IVIG might have a broad spectrum of effects on the immune response. For instance, IVIG treatment is believed to neutralize circulating DSA, inhibit complement activation and engage Fc receptors on immune effector cells (99). In lung transplantation, IVIG treatment alone does not sufficiently influence the humoral response (100) and is therefore often employed in combination with other agents (101).

To suppress antibody production, different therapeutics targeting the B cell response are available. Rituximab is a chimeric monoclonal anti-CD20 antibody inducing apoptosis in mature B cells. However, plasma cells lack CD20 surface expression and thus are not targeted by rituximab. Therefore, a reduction of antibody titers is observed with a delay of three months after the natural demise of short-lived plasma cells (102). In addition, LLPCs also lack CD20 expression, and thus rituximab cannot entirely abrogate the humoral response. In sensitized lung transplant recipients, rituximab is therefore often combined with antibody reduction strategies. In a prospective study, rituximab safely contributed to DSA reduction in combination with IVIG (103).

The anti-CD19 antibody inebilizumab can target a broader range of B lymphocytes as CD19 is conserved in plasma cells. In neuromyelitis optica, inebilizumab efficiently reduces pathologic antibody titers (104) and it is currently under clinical investigation for desensitization prior to renal transplantation (ClinicalTrials.gov Identifier: NCT04174677). However, evidence suggests that inebilizumab may not target LLPCs as these cells are not effectively targeted by CD19-directed CAR T-cell therapy (105).

When aiming to inhibit antibody production, plasma cells ought to be the primary therapeutic target. Proteasome inhibitors such as bortezomib and carfilzomib are small molecules first approved for use in multiple myeloma that deplete plasma cells by inducing apoptosis. In lung transplantation, proteasome inhibitors are used within multimodal concepts for desensitization and treatment of AMR (106, 107). However, beneficial long-term effects cannot be achieved with proteasome inhibitors. In vitro, they have been demonstrated to induce apoptosis in memory B cells. Thus, their lack of long-term efficiency can probably be attributed to the persistent activity of LLPCs in the bone marrow. Of note, bortezomib treatment is limited by cumulative dose-related toxicity and can have severe toxic pulmonary effects (108). Thus, caution should be taken when applying it to lung transplant recipients.

Therapeutically targeting LLPCs in the bone marrow niche is a significant hurdle to inhibiting alloantibody production. LLPCs evade B cell depletion strategies by altered expression of B cell markers and their upkeep is independent of T cell help. Plerixafor is a novel CXCR4 chemokine antagonist used to mobilize hematopoietic stem cells from the bone marrow (109). As LLPC homing is CXCR4-dependent, plerixafor could also achieve their mobilization (110). In murine studies, plerixafor treatment primarily mobilized splenic plasma cells (111). In a non-human primate model of sensitized renal transplantation, combining plerixafor with the plasma cell-directed anti-CD38 antibody daratumumab resulted in a reduction of DSA and prolonged graft survival (112). However, daratumumab treatment was associated with DSA rebound and robust T cell-mediated rejection (112). In clinical use, authors report on cases of successful employment of daratumumab for desensitization and AMR treatment (112). Currently, the safety of anti-CD38 antibody treatment for desensitization before kidney transplantation is evaluated in a phase Ib/II study (ClinicalTrials.gov Identifier: NCT04294459).

Belimumab is a monoclonal antibody targeting the cytokine B lymphocyte stimulator (BLYS) critical for B lymphocyte survival. As such, it has been proposed to limit plasma cell survival and could thus reduce humoral alloimmunity (113). In animal studies, BLYS inhibition resulted in DSA reduction and prolonged graft survival (114, 115). The use of belimumab has been evaluated in human kidney transplantation, demonstrating a good safety profile. However, authors did not find a significant influence on B cell populations (116). Use of belimumab in lung transplantation has not been reported to date.

The anti-IL-6-receptor antibody tocilizumab licensed for use in rheumatoid arthritis can have beneficial effects on B cell development in the context of transplantation (117). IL-6 is an essential cytokine for plasma cell differentiation, and IL-6-deficient mice present a reduction in IgG production (118, 119). In the context of lung transplantation, increased IL-6 is associated with primary graft dysfunction (120). In CLAD, the use of tocilizumab resulted in slight improvements in spirometry and DSA reduction (121).

Antithymocyte globulin (ATG) consists of polyclonal antibodies generated by applying human thymic tissue lysates to animals. Thus, ATG is directed against a wide variety of lymphocyte surface markers, including B cells. However, ATG more reliably affects T cells, and it is often reported that B cells are the predominating cell type persistent after treatment. Thus, ATG does not inhibit antibody production. However, the use of
ATG in lung transplantation has been reported in various stages of graft damage and can ameliorate acute (122) and chronic graft rejection (123). ATG may convey protective effects by interfering with T cell support for B cell reactions.

Costimulation can be targeted therapeutically by the fusion proteins belatacept and abatacept consisting of human IgG1 Fc fragments and the extracellular CTLA-4 domain. By competitive binding to CD80 and CD86, these molecules prevent CD28 costimulation and, consequently, the activation of naïve T cells (124). These agents are approved for second-line maintenance immunosuppression in kidney transplantation, substituting calcineurin inhibitors. Evidence suggests that belatacept limits de novo DSA production (125). In lung transplantation, successful use of belatacept in maintenance immunosuppression has been reported (126) and its use is currently being formally evaluated (ClinicalTrials.gov Identifier: NCT03388008).

**SUMMARY AND CONCLUSION**

B lymphocytes significantly contribute to the alloimmune response by antibody production and potentially by the modulation of the T cell response via antigen-presentation and cytokine secretion. Mainly, humoral responses cause hyperacute rejection and AMR. Clinically, sensitized lung transplant candidates face higher waitlist mortality and a reduced risk of rejection and AMR. Clinically, sensitized lung transplant candidates face higher waitlist mortality and a reduced likelihood to be transplanted. Post-transplantation, antibody-mediated rejection can lead to a rapid loss of graft function and is associated with CLAD development. In chronic rejection, B lymphocytes initiate lymphoid neogenesis associated with a pronounced local immune response and a rapid functional decline – especially observed in the RAS phenotype. Thus, B cellular responses pose a significant hurdle to long-term pulmonary graft survival. Several therapeutic strategies aiming to tone down B cell responses and thus reduce circulating DSA are employed in the clinic. However, their success is limited. In clinical use, a combination therapy is recommended as no single agent can sufficiently diminish the B cell response alone. Multiple substances are necessary to target all, antibody-mediated graft injury, antibody production and plasma cell differentiation. Currently, several novel B cell-targeted therapeutic agents are under evaluation for kidney or lung transplantation. However, these immunosuppressants do not only inhibit the pathological immune reactions after transplantation but they also influence lymphocyte subsets with regulatory properties. Immunoregulatory B cells remain poorly characterized to date due to a lack of specific markers. Thus, selective inhibition of alloreactive B cells preserving Breg functions has not been achieved to date but may be a promising strategy to prolong pulmonary allograft and recipient survival in the future.

**AUTHOR CONTRIBUTIONS**

BO drafted and wrote the manuscript. WJ drafted and wrote the manuscript. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

All figures were created using BioRender.com. We further acknowledge support by the Open Access Publication Fund of the University of Freiburg.

**REFERENCES**

1. Chambers DC, Yussen RD, Cherikh WS, Goldfarb SB, Kucheryavaya AY, Khusk K, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-Fourth Adult Lung and Heart-Lung Transplantation Report-2017; Focus Theme: Allograft Ischemic Time. *J Hear Lung Transpl* (2017) 36:1047–59. doi: 10.1016/j.healun.2017.07.016
2. Levine DJ, Glanville AR, Aboyoun C, Belperio J, Benden C, Berry GJ, et al. Antibody-Mediated Rejection of the Lung: A Consensus Report of the International Society for Heart and Lung Transplantation. *J Hear Lung Transpl* (2016) 35:397–406. doi: 10.1016/j.healun.2016.01.1223
3. Koenig A, Thaunat O. Lymphoid Neogenesis and Tertiary Lymphoid Organs in Transplanted Organs. *Front Immunol* (2016) 7:1–9. doi: 10.3389/fimmu.2016.00646
4. Chong AS, Khiew SH. Transplantation Tolerance: Don’t Forget About the B Cells. *Clin Exp Immunol* (2017) 189:171–80. doi: 10.1111/cei.12927
5. Frost AE, Jammal CT, Cagle PT. Hyperacute Rejection Following Lung Transplantation. *Chest* (1996) 110:559–62. doi: 10.1378/chest.110.2.559
6. Cleary SJ, Kwaan N, Tian JJ, Calabrese DR, Mallavia B, Magnen M, et al. Complement Activation on Endothelium Initiates Antibody-Mediated Acute Lung Injury. *J Clin Invest* (2020) 130:5909–23. doi: 10.1172/JCI138136
7. Cunningham AC, Zhang JG, Moy JV, Ali S, Kirby JA. A Comparison of the Antigen-Presenting Capabilities of Class II MHC-Expressing Human Lung Epithelial and Endothelial Cells. *Immunology* (1997) 91:458–63. doi: 10.1046/j.1365-2567.1997.doi-12249.x
8. Kreisel D, Richardson SB, Li W, Lin X, Kornfeld CG, Sugimoto S, et al. MHC Class II Expression by Pulmonary non-Hematopoietic Cells Plays a Critical Role in Controlling Local Inflammatory Responses. *J Immunol* (2010) 185:3809–13. doi: 10.4049/jimmunol.1000971
9. Valenzuela NM, McNamara JT, Reed EF. Antibody-Mediated Graft Injury: Complement-Dependent and Complement-Independent Mechanisms. *Curr Opin Organ Transpl* (2014) 19:33–40. doi: 10.1097/MOT.0000000000000040
10. Saini D, Weber J, Ramachandran S, Phelan D, Tiriveedu V, Liu M. Alloimmunity Induced Autoimmunity as a Potential Mechanism In The Pathogenesis of Chronic Rejection of Human Lung Allografts. *J Heart Lung Transplant* (2011) 30:624–31. doi: 10.1016/j.healun.2011.01.708
11. Fukami N, Ramachandran S, Saini D, Walter M, Chapman W, Patterson GA, et al. Antibodies to MHC Class I Induces Autoimmunity: Role in the Pathogenesis of Chronic Rejection. *J Immunol* (2009) 182:309–18. doi: 10.4049/jimmunol.182.1.309
12. Amara U, Flierl MA, Rittisch D, Klos D, Chen H, Acker B, et al. Molecular Intercommunication Between the Complement and Coagulation Systems. *J Immunol* (2010) 185:5628–36. doi: 10.4049/jimmunol.182.1.309
13. Traysac M, Nègre-Salvatray A, Thomsen M. Mechanisms of Human Smooth Muscle Cell Proliferation and Transplant Vasculopathy Induced by HLA Class I Antibodies: In Vivo and In Vivo Studies. *Hum Immunol* (2012) 73:1253–60. doi: 10.1016/j.humimm.2012.06.012
14. Kuo HH, Morrell CN, Baldwin WM. Alloantibody Induced Platelet Responses in Transplants: Potent Mediators in Small Packages. *Hum Immunol* (2012) 73:1253–8. doi: 10.1016/j.humimm.2012.06.011
27. Gatto D, Wood K, Brink R. EBI2 Operates Independently of But in
34. Hiepe F, Dörner T, Hauser AJ, Hoyer BF, Mei H, Radbruch A. Long-Lived

3. Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and
20. Aversa M, Darley DR, Hirji A, Snyder L, Lyu D, Parquin D, et al. Approaches
18. Smith JD, Ibrahim MW, Newell H, Danskine AJ, Soresi S, Burke MM, et al. Outcomes and Donor-Specific Antibodies: Characteristics Causing Detrimental Effects on Survival After Lung Transplantation. J Heart Lung Transpl (2014) 33:1074–82. doi: 10.1016/j.healun.2014.02.033

17. Brugière O, Roux A, Le Pavec J, Sroussi D, Parquin F, Pradere P, et al. Role of C1q-Binding Anti-HLA Antibodies as a Predictor of Lung Allograft Rejection. Transpl Int (2014) 33:1074–82. doi: 10.1016/j.healun.2014.02.033

16. Legris T, Picard C, Todorova D, Lyonnet L, Laporte C, Dumoulin C, et al. Antibody-Dependent NK Cell Activation is Associated With Late Kidney Allograft Dysfunction and the Complement-Independent Allergicative Potential of Donor-Specific Antibodies. Front Immunol (2016) 7:288. doi: 10.3389/fimmu.2016.00288

Brugières O, Roux A, Le Pavec J, Sroussi D, Parquin F, Pradere P, et al. Role of C1q-Binding Anti-HLA Antibodies as a Predictor of Lung Allograft Outcome. Eur Respir J (2018) 52:1–11. doi: 10.1183/13993003.01896-2017

Smith ID, Ibrahim MW, Newell H, Danskine AJ, Sorens S, Burke MM, et al. Pre-Transplant Donor HLA-Specific Antibodies: Characteristics Causing Detrimental Effects on Survival After Lung Transplantation. J Heart Lung Transpl (2014) 33:1074–82. doi: 10.1016/j.healun.2014.02.033

18. Smith JD, Ibrahim MW, Newell H, Danskine AJ, Soresi S, Burke MM, et al. Approaches to the Management of Sensitized Lung Transplant Candidates: Findings From an International Survey. J Heart Lung Transpl (2020) 39:5315. doi: 10.1016/j.healun.2020.01.709

Young KA, Ali HA, Beermann KJ, Reynolds JM, Snyder JD. Lung Transplantation and the Era of the Sensitized Patient. Front Immunol (2021) 12:689420. doi: 10.3389/fimmu.2021.689420

16. Legris T, Picard C, Todorova D, Lyonnet L, Laporte C, Dumoulin C, et al. Antibody-Dependent NK Cell Activation is Associated With Late Kidney Allograft Dysfunction and the Complement-Independent Allergicative Potential of Donor-Specific Antibodies. Front Immunol (2016) 7:288. doi: 10.3389/fimmu.2016.00288

2. Globe D, Wood K, Brink R. EBI2 Operates Independently of But in
34. Hiepe F, Dörner T, Hauser AJ, Hoyer BF, Mei H, Radbruch A. Long-Lived

3. Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and
20. Aversa M, Darley DR, Hirji A, Snyder L, Lyu D, Parquin D, et al. Approaches
55. Zhang Q, Reed EF. The Importance of non-HLA Antibodies in Transplantation. *Nat Rev Nephrol* (2016) 12:484–95. doi: 10.1038/nrneph.2016.88.

56. Rao U, Sharma M, Mohanakumar T, Ahn C, Gao A, Kaza V. Prevalence of Antibodies to Lung Self-Antigens (Ktx1 Tubulin and Collagen V) and Donor Specific Antibodies to HLA in Lung Transplant Recipients and Implications for Lung Transplant Outcomes: Single Center Experience. *Transpl Immunol* (2019) 54:65–72. doi: 10.1016/j.trim.2019.02.006.

57. Benichou G, Alessandrini A, Charras R-S, Wilkes DS. Induction of Autoimmunity After Allotransplantation. *Front Biosci* (2007) 12:4362–9. doi: 10.2741/2393.

58. Yarkoni Y, Getahun A, Cambier JC. Molecular Underpinning of B-Cell Anergy. *Immunol Rev* (2010) 237:249–63. doi: 10.1111/j.1600-065X.2010.00936.x.

59. Cook MC, Basten A, Fazekas De St. Groth B. Rescue of Self-Reactive B Cells by Provision of T Cell Help In Vivo. *Eur. J Immunol* (1998) 28:2549–58. doi: 10.1002/(SICI)1521-4141(199808)28:08<2549::AID-IMMU2549>3.0.CO;2-O.

60. Win TS, Rehakova S, Negus MC, Rehakova S, Negus MC, Saeb-Parsy K, Goddard M, et al. B Cell Epitope Spreading: Mechanisms and Contribution to Autoimmune Diseases. *Immunol Lett* (2015) 163:56–68. doi: 10.1016/j.imlet.2014.11.001.

61. Cornaby C, McQuillan J, Gao B, Moore C, Porcheray F, Rong C, et al. Pre-Transplant IgG Reactivity to Apoptotic Cells Correlates With Late Kidney Allograft Loss. *Am J Transpl* (2014) 14:1581–91. doi: 10.1111/ajt.12763.

62. Porcheray F, Thirion T, Gao B, McQuillan J, Dargen I, et al. Polyclonal Antibodies Developing Amidst Humid Response of Human Kidney Grafts Bind Apoptotic Cells and Activate Complement. *Am J Transpl* (2013) 13:2590–600. doi: 10.1111/ajt.12394.

63. Budej K, van de Graaf EA, Kardol-Hoefnagel T, Oudijk EJD, Kwakkel-van Erp JM, Hack CE, et al. Antibodies Against Apoptotic Cells Present in End-Stage Lung Disease Patients do Not Correlate With Clinical Outcome After Lung Transplantation. *Front Immunol* (2017) 8:1–10. doi: 10.3389/fimmu.2017.00322.

64. Noorshams H, Reed AJ, Rostami SY, Mozaffari R, Zekavat G, Koeberlein B, et al. B Cell-Mediated Antigen Presentation is Required for the Pathogenesis of Acute Cardiac Allograft Rejection. *J Immunol* (2006) 177:7715–22. doi: 10.4049/jimmunol.177.11.7715.

65. Zhang AS. B Cells as Antigen-Presenting Cells in Transplantation Rejection and Tolerance. B Cells as Antigen-Presenting Cells in Transplantation Rejection and Tolerance. *Cell Immunol* (2020) 349:104061. doi: 10.1016/j.cellimm.2020.104061.

66. Wortel CM, Heidt S. Regulatory B Cells: Phenotype, Function and Role in Transplantation. *Transpl Immunol* (2017) 41:1–9. doi: 10.1016/j.trim.2017.02.004.

67. Alhabhab RY, Nova-Lamperti E, Aravena O, Burton HM, Lechler RI, Dorling A, et al. Regulatory B Cells: Development, Phenotypes, Functions, and Role in Transplantation. *Transplantation* (2019) 292:164–79. doi: 10.1111/trim.12800.

68. Gallichan AD, Remuzzi G, Harmon WE, Sayegh MH. Challenges to Achieving Clinical Transplantation Tolerance. *J Clin Invest* (2001) 108:943–5. doi: 10.1172/JCI00114142.

69. Ebert C, Schure-Bouwman L, Roelfsema W, Ruigrok RWH. Treatment of Hyperacute Rejection With Eculizumab, Intravenous Immunoglobulins, and Rituximab. *Transpl Immunol* (2019) 55:727. doi: 10.1016/J.LITR.2019.02.007.

70. Vionic R, Bertolet D, Hertler K, Aulad B, Moraes CR, et al. B-Cell-Dependent Autoantibody Production Associated With Reduced Long-Term Survival. *J Am Soc Nephrol* (2010) 21:1052–6. doi: 10.1681/ASN.2010020094.

71. Savelkoul HFJ. Current Understanding of the Immune Tolerance Network. *Nat Immunol* (2015) 16:57–68. doi: 10.1038/nature15301.

72. Mielle J, Audo R, Hahne M, Macia L, Combe B, Morel J, et al. IL-10 Mediate Chronic Allograft Rejection Independently of Antibody Production. *Immunol Lett* (2016) 163:56–70. doi: 10.1016/j.imlet.2014.11.001.

73. Nadine A, van Erp JM, Hack CE, et al. Antibodies Against Apoptotic Cells Present in Post-Transplant Serum Reactivity. *Front Immunol* (2018) 9:507. doi: 10.3389/fimmu.2018.005961.

74. Clatworthy MR, Watson CJ, Matta S, Bardsley V, Chaudhry AN, Bradley 3rd, et al. Efﬁcacy of Plasmapheresis on Donor-Specific Antibodies and Acute Antibody-Mediated Rejection 1 Week After Lung Transplantation. *Transplantation* (2017) 102:e301. doi: 10.1097/TP.0000000000002354.

75. Yamada C, Ramon DS, Cascalho M, Sung RS, Leichtman AB, Samaniego M, et al. Treatment of Hyperacute Antibody-Mediated Rejection Lung Allograft Rejection With Eculizumab. *J Heart Lung Transpl* (2012) 31:1325–6. doi: 10.1016/j.healun.2012.09.016.

76. Cooke MC, Basten A, Fazekas De St. Groth B. Rescue of Self-Reactive B Cells by Provision of T Cell Help In Vivo. *Eur. J Immunol* (1998) 28:2549–58. doi: 10.1002/(SICI)1521-4141(199808)28:08<2549::AID-IMMU2549>3.0.CO;2-O.
93. Parquin F, Cuqemelle E, Camps E, Devaque J, Houllibacq MP, Sage E, et al. CI-Esterase Inhibitor Treatment for Antibody-Mediated Rejection After Lung Transplantation: Two Case Reports. *Eur Respir J* (2020) 55:190227. doi: 10.1183/13993003.02027-2019
94. Thomas KA, Valenzuela NM, Gjertson D, Mulder A, Fishbein MC, Parry GC, et al. An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. *Am J Transplant* (2015) 15:2037–49. doi: 10.1111/ajt.13273
95. Mühlbacher J, Iljma B, Wahrmann M, Bartko J, Eskandary F, Schöngenhofer C, et al. Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results From a Randomized First-In-Human Phase I Trial. *Transplantation* (2017) 101:2410–8. doi: 10.1097/TP.0000000000001804
96. Eskandary F, Iljma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, et al. Anti-C1s Monoclonal Antibody BIVV009 in Late Antibody-Mediated Kidney Allograft Rejection-Results From a First-in-Patient Phase I Trial. *Am J Transplant* (2018) 18:916–26. doi: 10.1111/ajt.14528
97. Jordan SC, Lorant T, Choi J, Kjellman C, Winstedt L, Bengtsson M, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. *N Engl J Med* (2017) 377:442–53. doi: 10.1056/NEJMs1612567
98. Aitchinson MD, Kaveri SV. Immunomodulation of Autoimmune and Inflammatory Diseases With Intravenous Immune Globulin. *N Engl J Med* (2001) 345:747–55. doi: 10.1056/NEJMra993360
99. Levine MH, Abt PL. Treatment Options and Strategies for Antibody Mediated Rejection After Renal Transplantation. *Semin Immunol* (2012) 24:136. doi: 10.1016/j.smim.2011.08.015
100. Benedetti EC, Chery G, Hartwig M, Hultberg A, Reynolds J, Snyder L. Intravenous Immunoglobulin in Sensitized Lung Transplant Recipients and Early Outcomes. *J Heart Lung Transplant* (2016) 35:S237–8. doi: 10.1016/j.hejlt.2016.01.673
101. Snyder LD, Gray AL, Reynolds JM, Arepally GM, Bedoya A, Hartwig MG, et al. Antibody Desensitization Therapy in Highly Sensitized Lung Transplant Candidates. *Am J Transplant* (2014) 14:849. doi: 10.1111/ajt.12636
102. Ionescu L, Urschel S. Memory B Cells and Long-Lived Plasma Cells. *Transplantation* (2019) 103:890–8. doi: 10.1097/TP.0000000000002594
103. Hachem RR, Yusen RD, Meyers BF, Aloush AA, Mohanakumar T, Patterson GA, et al. Anti-Human Leukocyte Antigen Antibodies and Preemptive Antibody-Directed Therapy After Lung Transplantation. *J Heart Lung Transplant* (2010) 29:973–80. doi: 10.1016/j.hejlt.2010.05.006
104. Frampton JE. Inebilizumab: First Approval. *Drugs* (2020) 80:1259–60. doi: 10.1007/s40266-020-00268-6
105. Bhoj VG, Arhontoulis D, Werthe im G, Capobianchi J, Callahan CA, et al. Antibody Desensitization Therapy in Highly Sensitized Lung Transplant Candidates. *Am J Transplant* (2014) 14:849. doi: 10.1111/ajt.12636
106. Iasella CJ, Winstead RJ, Moore CA, Johnson BA, Feinberg AT, Morrell MR, et al. In Vivo Effects of the Anti-Interleukin-6 Receptor Inhibitor Ticilizumab on the B Cell Compartment. *Arthritis Rheumatol* (2011) 63:1255–64. doi: 10.1002/art.30242
107. Kopf M, Herren S, Wiles MV, Pepys MB, Kosco-Vilbois MH. Interleukin 6 Inhibitors Fuel Central Development and Antibody Production via a Contribution of C3 Complement Component. *J Exp Med* (1998) 188:1895–906. doi: 10.1084/jem.188.10.1895
108. Verleden SE, Martens A, Vandermeulen E, Bellon H, Heigl T, Sacrea A, et al. The Association of IL-6 and IL-8 Within 72 Hours Post-Transplant and Short and Long Term Outcome. *J Heart Lung Transplant* (2017) 36:S5187. doi: 10.1016/j.hejlt.2017.01.492
109. Ross DJ, Der Hovanessian A, Kubak B, Reed E, Natori C, Schaeumann J, et al. Combination Therapies Including Ticilizumab Decrease the Progression of CLAD: Initial Clinical Experience. *J Heart Lung Transplant* (2019) 38:S405. doi: 10.1016/j.hejlt.2019.01.1032
110. Palmer SM, Miralles AP, Lawrence CM, Gaynor JW, Davis RD, Tapson VF. Daratumumab in Sensitized Kidney Transplantation: Potentials and Challenges. *Drugs* (2020) 80:1259–60. doi: 10.1007/s40266-020-00268-6
111. Ensor CR, Goehring KC, Iselja CJ, Moore CA, Lendermon EA, Dymyr JF, et al. Belatacept for Maintenance Immunosuppression in Cardiothoracic Transplantation: The Potential Frontier. *Clin Transplant* (2018) 32:e13363. doi: 10.1111/ctr.13363
112. Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, et al. De Novo Donor-Specific Antibodies in Belatacept-Treated vs Cyclosporine-Treated Kidney-Transplant Recipients: *Post Hoc Analyses of the Randomized Phase III BENEFIT and BENEFIT-EXT Studies.* *Am J Transplant* (2018) 18:1783–9. doi: 10.1111/ajt.14721
113. Iselja CJ, Winstead RJ, Moore CA, Johnson BA, Feinberg AT, Morrell MR, et al. Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors. *Transplantation* (2018) 102:171–7. doi: 10.1097/TP.0000000000001873

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in
